Neoadjuvant Lenvatinib and Pembrolizumab for IVC Tumor Thrombus
Phase 2
30
about 3.7 years
18+
1 site in TX
What this study is about
Researchers are testing the safety and effectiveness of lenvatinib and pembrolizumab given before surgery to people with locally advanced kidney cancer that has spread into the inferior vena cava (IVC). The goal is to see if this combination treatment helps remove the tumor. The trial will last for about 1333 days.
Simplified from trial records by PatientMatch.
What you may be asked to do
- 1.Take Adjuvant Pembrolizumab
- 2.Take Neoadjuvant Lenvatinib
- 3.Take Neoadjuvant Pembrolizumab
- +1 more
Participation Burden
What's physically and logistically required of participants.
Requires travel to a study site
How treatment is administered
Everyone gets the investigational treatment.
Extracted study details
Pulled from the trial record to show what is being tested and what the study is measuring.
immunotherapy (Immune checkpoint inhibitor; blocks PD-1 to boost T-cell attack on cancer)
oral (Oral Capsule), infusion
Primary: Disease Control Rate
Secondary: Estimated blood loss, Length of stay, Operative time
Oncology